Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14543572 | 0.88 | KMT2A (0.50) | ALDH1A1KMT2AMEN1KDM4ETSHR | |
| SCHEMBL11515591 | 0.87 | TSHR (0.66) | ALDH1A1KMT2AMEN1KDM4ETSHR | |
| SCHEMBL19073513 | 0.86 | KMT2A (0.49) | ALDH1A1KMT2AMEN1KDM4ETSHR | |
| SCHEMBL27978253 | 0.86 | CA12 (0.49) | ALDH1A1TDP1KMT2AMEN1KDM4E | |
| SCHEMBL13516645 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TDP1KMT2AMEN1KDM4E | |
| SCHEMBL8514914 | 0.85 | SMN1; SMN2 (0.50) | ALDH1A1TDP1KMT2AMEN1KDM4E | |
| SCHEMBL572 | 0.85 | KMT2A (0.58) | ALDH1A1TDP1KMT2AMEN1KDM4E | |
| SCHEMBL10539937 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TDP1KMT2AMEN1TSHR | |
| SCHEMBL8585196 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1KDM4ETSHR | |
| SCHEMBL8085697 | 0.84 | CA12 (0.61) | ALDH1A1TDP1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558833-B | Pyrazole alcohol compound, pharmaceutical composition thereof and application thereof in medicines | 贵州医科大学 | 2022-03-04 | — | — | CN | disclosed |
| EP-2699577-A1 | TETRAHYDROPYRAZOLO [1,5 -A]PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS | Glaxo Group Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| CN-103596958-A | Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds | GLAXO GROUP LTD | 2014-02-19 | — | — | CN | disclosed |
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| WO-2012143522-A1 | TETRAHYDROPYRAZOLO [1,5 -A] PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1003740-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGOISTS | Abbott Laboratories (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | TBL3, NDUFV3, NME2 | ALDH1A1 1939/4885TDP1 2101/4885KMT2A 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.